Sustained release formulations BE [Design Issues]

posted by Ahmed meeran – 2006-11-21 13:24 (6365 d 07:33 ago) – Posting: # 368
Views: 4,716

Dear Dr. Helmut

Kindly advise me how to conduct BE for a sustained release formulation in UK/EU. Both the innovator and test products are sustained release formulation of same strength. Whether the studies have to be conducted in s.s.a designs. Whether Both fasting and fed BE has to be conducted. Whether BW can be applied based on the highest dose strength if IVIVC performed. If IVIVC has to be performed on what method. is it by Wagner or Loo - Reigelmann method (but no oral solution data is available) or numerical deconvulation method to be used. Kindly clarify

Sincerly,

D.Ahmed

Complete thread:

UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,651 registered users;
131 visitors (0 registered, 131 guests [including 5 identified bots]).
Forum time: 21:57 CEST (Europe/Vienna)

Never never never never use Excel.
Not even for calculation of arithmetic means.    Martin Wolfsegger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5